1
|
Shargian-Alon L, Yahav D, Rozovski U, Dovrat S, Amitai I, Sela-Navon M, Pasvolsky O, Raanani P, Yeshurun M. Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation - a single-center experience. Leuk Lymphoma 2019; 60:2230-2236. [PMID: 30773083 DOI: 10.1080/10428194.2019.1576869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Data regarding presentation and management of human herpes virus 6 (HHV-6) reactivation among autologous hematopoietic cell transplantation (HCT) recipients are limited. We retrospectively reviewed medical charts of all autologous HCT patients tested for HHV-6 reactivation due to suspected clinical presentation between 1/2012 and 8/2017. Among 328 autologous HCT recipients, 44 patients were tested for HHV-6 reactivation. Thirty patients tested positive; 29 (97%) had sustained fever, six (20%) had rash and four (13%) had pneumonia. Median C-reactive protein was significantly lower in HHV-6 positive patients compared to negative patients (3.6 (range, 0.4-11) vs. 9.6 (range, 3.2-30) mg/dL, respectively, p = .004). Ganciclovir formulations were administrated in 29 (97%) patients with median time to fever resolution of one (range, 1-2) day. HHV-6 should be considered as an important cause of post engraftment fever in autologous HCT. Larger studies are warranted to evaluate incidence of HHV-6 reactivation and optimal treatment regimen.
Collapse
Affiliation(s)
- Liat Shargian-Alon
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.,Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
| | - Dafna Yahav
- Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel.,Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital , Petah-Tikva , Israel
| | - Uri Rozovski
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.,Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
| | - Sara Dovrat
- Central Virology Laboratory, Israel Ministry of Health, Chaim Sheba Medical Center , Tel-Hashomer , Israel
| | - Irina Amitai
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.,Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
| | - Michal Sela-Navon
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel
| | - Oren Pasvolsky
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.,Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
| | - Pia Raanani
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.,Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
| | - Moshe Yeshurun
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.,Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
| |
Collapse
|